1 active not recruiting, 1 completed, 1 not yet recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow wetAMD: new trials by email Literature Review of wetAMD trials Research Report on wetAMD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration SCAI-005 0.04% 2drops TID, SCAI-005 0.08% 2drops TID, Placebo 2drops TID - wetAMD, Age Related Macular Degeneration | Phase 2 | Not yet recruiting | SCAI Therapeutics | 50 | 2026-11-01 | 2026-05-26 |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
| Canadian Treat and Extend Analysis Trial With Ranibizumab 0.5 mg Ranibizumab intravitreal injections - wetAMD | Completed | Novartis Pharmaceuticals | 505 | 2013-05-08 | 2020-06-05 |
Macular Degeneration (3) · Choroidal Neovascularization (1) · Eye Diseases (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Wet Macular Degeneration (1)
Eye Diseases (2) · Retinal Degeneration (2) · Retinal Diseases (2) · Choroid Diseases (1) · Eye Diseases, Hereditary (1) · Metaplasia (1) · Neovascularization, Pathologic (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Uveal Diseases (1)
aflibercept (1)
AbbVie (1) · Novartis Pharmaceuticals (1) · SCAI Therapeutics (1)
Canada (2) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1) · United States (1)